Autoimmune Diseases
Guidelines
New EULAR lupus recommendations advise using biologics, tapering steroids
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and...
Conference Coverage
Patient selection key to lowering placebo response rates in lupus clinical trials
High placebo response rates in lupus clinical trials are making it difficult to show treatment effectiveness.
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Conference Coverage
Encouraging telitacicept results reported in phase 3 for lupus, phase 2 for Sjögren’s
Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept,...
Latest News
Scientists discover variants, therapy for disabling pansclerotic morphea
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.
Conference Coverage
Investigational lupus drug cenerimod moves to phase 3 studies after equivocal phase 2 results
Novel S1P1 receptor modulator cenerimod shows impact on disease activity in lupus, with more pronounced benefits in those with more severe disease...
Conference Coverage
Severe hydroxychloroquine nonadherence linked to worse SLE outcomes
Severe nonadherence to hydroxychloroquine in patients with lupus is associated with an increased risk of flare, organ damage, and mortality within...
Latest News
Lupus landmark study aims for personalized medicine goals
The Lupus Landmark Study was designed as part of the Lupus Nexus, a combination registry, biorepository, and data portal.
From the Journals
Cutaneous vasculitis curtails quality of life
Survey respondents described a generally poor health-related quality of life that was detailed as more severe with a skin-specific instrument than...
From the Journals
IVIG shows no impact on VTE risk in dermatomyositis patients
The rate of venous thromboembolism did not increase in dermatomyositis patients treated with intravenous immunoglobulin, compared with those not...
News from the FDA/CDC
FDA fast tracks potential CAR T-cell therapy for lupus
The cellular therapy depletes CD19-positive B cells with the goal of ‘‘resetting’’ the immune system to achieve durable remission.